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Summary
Tumor cells with mutated PTEN proliferate in an EGFR-independent manner. Induction of PTEN sensitizes cells to EGFR
inhibition, and the combination causes synergistic apoptosis. Synergy is due to inhibition of two parallel pathways that
phosphorylate the proapoptotic protein BAD at distinct sites. Serine 112 phosphorylation is EGFR/MEK/MAPK dependent,
whereas serine 136 phosphorylation is PI3K/Akt dependent. Either phosphorylation is sufficient to sequester BAD to 14-
3-3. BAD is released and apoptosis is induced only if both serines are dephosphorylated in response to inhibition of both
pathways. Reduction of BAD expression by RNA interference prevents apoptosis in response to pathway inhibition. Thus,
BAD integrates the antiapoptotic effects of both pathways. Combined inhibition of EGFR and PI3K signaling may be a
useful therapeutic strategy.S I G N I F I C A N C E
We demonstrate that restoration of PTEN expression causes PTEN-deficient tumor cells to depend on EGFR for survival. The BAD protein
acts as a switch that integrates the antiapoptotic effects of the EGFR/MAPK and PI3K/Akt pathways. Inhibition of both pathways is
required to release BAD from 14-3-3 and activate its proapoptotic functions. The data provide a heuristic model for understanding
pathway interactions that allows the development of rational strategies for combination therapy and reveals a potential clinical
role for inhibition of wild-type EGFR. Thus, EGFR inhibitors may be useful in combination with inhibitors of PI3K/Akt kinase signaling
for the treatment of glioblastomas, prostate cancer, and other tumors in which EGFR activation and PTEN mutation coexist.Introduction
In normal cells, proliferation is regulated by a complex network
of pathways that transduces signals from activated growth fac-
tor receptors. Stimulation of these receptor-activated pathways
results in progression through the cell cycle but also acts to
suppress the apoptotic machinery and has many other conse-
quences that result in regulated proliferation. The EGFR tyro-
sine kinase is an important regulator of the proliferation of nor-
mal epithelial cells (Olayioye et al., 2000). EGFR (HER1) is one
of four members of the HER kinase family of receptors. These
receptors are activated by ligand-dependent homo and hetero-
dimerization, which leads to kinase activation, auto- and trans-
phosphorylation of their intracellular domains, and initiation of
signaling. HER kinase activation leads to stimulation of diverse
pathways, including those comprised of Ras/Raf/MEK/MAPK,
phospholipase C, and STAT (Yarden and Sliwkowski, 2001).
trans-phosphorylation of HER3 causes potent activation of
phosphatidylinositol-3 kinase (PI3K)/Akt signaling, but phos-
phorylation of EGFR itself is only a weak activator of this path-
way (Soltoff et al., 1994).
EGFR-activated signaling stimulates cell cycle progression,
regulates cell shape and motility, and inhibits apoptosis
(Woodburn, 1999; Yarden and Sliwkowski, 2001). Mutational or
autocrine activation of the receptor leads to unregulated prolif-
eration and malignant transformation in model systems and inCANCER CELL : OCTOBER 2005 · VOL. 8 · COPYRIGHT © 2005 ELSEVIERspecific cellular contexts (De Luca et al., 1999; Huang et al.,
1997; Moscatello et al., 1998; Salomon et al., 1995). Naturally
occurring mutations of EGFR have been detected in a signifi-
cant proportion of patients with glioblastomas (Frederick et al.,
2000) and in non-small cell lung cancer (Paez et al., 2004; Pao
et al., 2004). The level of expression of EGFR has also been
correlated with poor prognosis in a variety of tumors.
These studies on the physiologic role of EGFR in normal
cells, the functional consequences of its activation, and its as-
sociation with various malignancies led to the hypothesis that
it may be a therapeutic target. A variety of inhibitors of HER
family tyrosine kinase activity, some selective for EGFR, and
several antibodies that bind to the extracellular domains of
EGFR and HER2 have been developed (Harari, 2004; Mendel-
sohn and Baselga, 2000). However, the clinical activity of these
strategies has been restricted to a small number of patients.
Small molecule inhibitors of EGFR have antitumor activity in
the subset (10%–30%) of patients with lung cancer whose tu-
mors harbor EGFR mutations (Paez et al., 2004). Overt antitu-
mor activity is rare in patients with wild-type EGFR and in most
tumor types. Anti-EGFR antibodies have antitumor activity in
very few patients and marginally sensitize some tumors to che-
motherapy and radiation, but the effects are subtle (Baselga et
al., 2000; Shin et al., 2001).
The data suggest that EGFR may not play an important role
in most carcinomas. Indeed, in several model systems, onco-INC. DOI 10.1016/j.ccr.2005.09.006 287
A R T I C L Egenic transformation of normal epithelial cells abrogates their
dependence on EGFR for proliferation or survival (Markowitz et
al., 1994). This is perhaps understandable; Ras, B-Raf, PI3K,
PTEN, and Akt are all downstream targets of EGFR that are
mutated at high frequency in various malignancies (Li et al.,
1997; Samuels et al., 2004; Tsao et al., 2004). The proliferation
of tumor cells with PTEN mutation is not dependent on EGFR,
but restoration of PTEN expression sensitizes them to EGFR
inhibition (Bianco et al., 2003; She et al., 2003b). We have now
uncovered a mechanism for this phenomenon. Induction of
PTEN expression inhibits Akt activity in these cells, slows their
growth, and markedly sensitizes them to induction of apopto-
sis by gefitinib (Iressa, ZD1839), a selective inhibitor of EGFR
tyrosine kinase. Synergy is due to inhibition of two parallel
pathways, EGFR/MEK/MAPK and PI3K/Akt, that regulate the
function of the proapoptotic protein BAD by phosphorylating it
on distinct sites, serines 112 and 136, respectively. Phosphory-
lation at either site is sufficient to cause BAD to bind to 14-3-3,
sequestering it from its effector molecules. BAD is released
from 14-3-3 and apoptosis is induced maximally only if both
serines are dephosphorylated in response to inhibition of both
pathways. Our data demonstrate that the BAD protein is a
switch integrating the antiapoptotic effects of multiple path-
ways that suppress apoptosis in PTEN-deficient tumor cells.
Results
Proliferation of tumor cells with PTEN mutation
is not dependent on EGFR
MDA-468 is a breast cancer cell line in which EGFR expression
is elevated and the PTEN gene is mutated (Li et al., 1997). In
order to study whether cellular dependence on EGFR is depen-
dent on PTEN, we established MDA-468TR-PTEN cells in
which PTEN expression is inducible by tetracycline (She et al.,
2003b). PTEN expression was maximally induced 3 hr after ex-
posure to 100 ng/ml doxycycline (Figure 1A). PTEN was in-
duced to levels similar to those in SkBr3 breast cancer cells
and slightly lower than those in the BT474 cell line (data not
shown). Induction of PTEN expression effectively inhibited
(>90%) phosphorylation of Akt and caused a slowing of growth
in tissue culture, but proliferation did continue (Figures 1A and
1B). We and others have previously shown that expression of
PTEN sensitizes these cells to EGFR inhibition (Bianco et al.,
2003; She et al., 2003b). The proliferation of normal epithelia is
EGFR dependent, and sensitive tumor cells are inhibited by the
EGFR inhibitor gefitinib over a concentration range of 50–700
nM (Baselga et al., 2002; Moasser et al., 2001), whereas MDA-
468 cells were inhibited by concentrations (5–6 M) far ex-
ceeding those required to inhibit EGFR (Figure 1C). Induction
of PTEN sensitized MDA-468 cells to much lower doses of gef-
itinib consistent with those required for EGFR inhibition (IC50s
in 600–700 nM range).
PTEN restoration sensitizes cells to induction
of apoptosis by EGFR inhibitors
The sensitization of MDA-468 cells to gefitinib by PTEN was
not due to an effect on their proliferation. Neither PTEN induc-
tion nor the PI3K inhibitor LY294002, alone or in combination
with gefitinib, affects the cell cycle distribution of MDA-468
(data not shown). Instead, a synergistic induction of apoptosis
was observed when gefitinib was administrated in combination288Figure 1. Induction of PTEN in tumor cells with PTEN mutation sensitizes them
to EGFR inhibition
A: MDA-468TR-PTEN cells were treated with 100 ng/ml doxycycline (Dox)
and harvested at the indicated times. Cell lysates were immunoblotted
with the indicated antibodies.
B and C: MDA-468TR-PTEN and vector control cells were treated with or
without Dox (100 ng/ml) (B), or with Dox in combination with gefitinib for 6
days (C). Results represent mean ± SE from three independent experiments
(B) or are shown as a percentage of cell number relative to gefitinib-
untreated control cells (C).with PTEN induction (Figure 2A) or LY294002 (Figure 2B). Sim-
ilar results were obtained in SKMG-3 glioblastoma cells, which
also overexpress EGFR and are PTEN null (Thomas et al.,
2001) (Figure S1 in the Supplemental Data available with this
article online). Gefitinib alone had little effect on apoptosis, and
PTEN induction had a modest effect (increase from 5% to 13%
at 72 hr), but the combination induced a marked and synergis-
tic induction (31%) of apoptosis as assessed by increased
sub-G1 fraction or by DNA fragmentation (Figures 2A–2C). In-
duction of PTEN in combination with gefitinib treatment caused
synergistic activation of caspase-3, a key effector of apoptosis,
by 24 hr (Figure 2D) and substantially increased levels of
cleaved PARP, a caspase-3 substrate (data not shown) (Nichol-
son et al., 1995). Furthermore, the induction of apoptosis by
the combination was markedly inhibited by the broad spectrum
caspase inhibitor Z-VAD-FMK (Figure 2E). Thus, inhibition of
PI3K renders these cells dependent on EGFR for suppression
of caspase-3-dependent apoptosis.
Inhibition of Akt signaling is required to sensitize
PTEN-deficient tumor cells to EGFR inhibitors
Induction of PTEN expression results in a marked decline in
intracellular Akt activity. Myristoylated Akt (Myr-Akt) is constitu-CANCER CELL : OCTOBER 2005
A R T I C L EFigure 2. Inhibition of both PI3K and EGFR synergistically induces apoptosis via activation of caspase-3
A and B: MDA-468TR-PTEN and control cells were treated with 3 M gefitinib or DMSO (<0.1%) with or without Dox (100 ng/ml) (A). MDA-468 cells were
treated with gefitinib and LY294002 for 72 hr (B). The fraction of apoptotic cells (sub-G1) was determined by flow cytometry, and the results represent
mean ± SE from three independent experiments.
C: MDA-468TR-PTEN and control cells were treated with 3 M gefitinib or DMSO (<0.1%) with or without Dox (100 ng/ml) for 8 hr and then assessed for
DNA fragmentation.
D: MDA-468TR-PTEN cells were treated with 3 M gefitinib or DMSO (<0.1%) with or without Dox (100 ng/ml). Cell lysates were immunoblotted for the active
fragment of caspase-3 and β-actin.
E: MDA-468TR-PTEN and control cells were pretreated with 100 M caspase inhibitor Z-VAD-FMK, for 1 hr followed by 3 M gefitinib or DMSO (<0.1%) with
or without Dox (100 ng/ml) for 72 hr. Apoptotic cells (sub-G1) were determined as in A, and the results represent mean ± SE from two independent experi-
ments.tively localized to the membrane (Alessi and Cohen, 1998), and
when it was transiently expressed in MDA-468 cells, induction
of PTEN no longer inhibited the phosphorylation of Akt (Figure
3B). Furthermore, induction of PTEN did not sensitize Myr-Akt-
expressing cells to gefitinib (Figure 3A). Thus, induction of apo-
ptosis requires PTEN-dependent downregulation of Akt ki-
nase activity.
EGFR inhibition affects MAP kinase
but not Akt kinase activation
Loss of Akt activity is necessary, but not sufficient, for the syn-
ergistic induction of apoptosis by PTEN and gefitinib. Induction
of PTEN in MDA-468 cells markedly reduced Akt phosphoryla-
tion but not MAPK phosphorylation (Figure 4A). Three micro-
molar gefitinib, a concentration in excess of that required for
maximal reduction of EGFR and HER2 phosphorylation in
these cells (Bianco et al., 2003; Moasser et al., 2001), inhibited
MAPK phosphorylation in either PTEN-expressing or controlCANCER CELL : OCTOBER 2005cells (Figure 4B). However, phosphorylation of Akt was unaf-
fected by gefitinib in PTEN-deficient cells, and it did not further
reduce Akt activity after PTEN induction. Similarly, in SKMG-3
cells, phosphorylation of Akt was affected by the PI3K inhibitor
LY294002, but not by gefitinib (Figures S1 and S2).
The data suggest that PI3K/Akt is EGFR independent in
these cells. To confirm this conclusion, the effect of gefitinib
on the association of PI3K with HER kinases in MDA-468 cells
was assessed. HER3 has no tyrosine kinase activity, but con-
tains multiple tyrosines that, when phosphorylated, are high
affinity docking sites for PI3K (Soltoff et al., 1994). Treatment
of MDA-468 cells with gefitinib inhibited EGFR phosphorylation
and markedly reduced the association of EGFR with HER3
(Figure 4C). However, the tyrosine phosphorylation of HER3
was not inhibited by gefitinib, and the interaction of HER3 with
the PI3K p85 regulatory subunit was insensitive to gefitinib.
Furthermore, HER3-associated PI3K activity was also unaf-
fected (Figure 4D). In contrast, in A431 tumor cells with wild-289
A R T I C L EFigure 3. Constitutively active Akt prevents apoptosis induced by PTEN in-
duction in combination with gefitinib
A and B: MDA-468TR-PTEN cells were transfected with myristoylated Akt
(Myr-Akt) or vector control. Cells were then treated with 3 M gefitinib or
DMSO (<0.1%) with or without Dox (100 ng/ml). Apoptotic cells (sub-G1)
were determined as in Figure 2A, and the results represent mean ± SE from
three independent experiments (A). Levels of phosphorylated Akt, total
Akt, and β-actin were assessed by immunoblotting (B).type PTEN that are sensitive to EGFR inhibitors, gefitinib inhib-
ited the interaction of p85 with HER3, HER3-associated PI3K
activity (Figures 4C and 4D), and Akt phosphorylation (Moasser
et al., 2001). Thus, in MDA-468 cells, the inhibition of Akt that
is required for the induction of apoptosis by the combination
of gefitinib and PTEN induction is entirely due to the latter. In
these cells, the PI3K/Akt pathway is not driven by EGFR.
How, then, does EGFR inhibition affect tumor cells in which
PI3K is inhibited by PTEN? Gefitinib effectively inhibits MAPK
phosphorylation in MDA-468 cells, whether or not PTEN ex-
pression has been induced (Figure 4B). The selective MEK
kinase inhibitor CI-1040 (Sebolt-Leopold, 2004) was used to
determine whether the consequences of MEK/MAPK inhibition
were similar to those of EGFR inhibition. Induction of PTEN or
inhibition of PI3K with LY294002 caused 2- to 3-fold sensitiza-
tion of MDA-468 cells to MEK inhibition (Figures 5A and 5B).
CI-1040 also synergized with PTEN or LY294002 to induce
apoptosis (Figures 5C and 5D). We tested the effects of com-
bined inhibition of MEK and PI3K in two other tumor cell lines
with PTEN deletion. SKMG-3 is a glioblastoma with high levels290of expression of EGFR (Thomas et al., 2001); SKMel-11 is a
melanoma with PTEN deletion in which MAPK is driven by mu-
tated B-Raf (Tsao et al., 2004). CI-1040 and LY294002 induced
synergistic apoptosis in both of the cell lines as well (Figures
5E and 5F). These data show that in tumor cells with PTEN
deletion and significant activation of MAPK, inhibition of PI3K/
Akt signaling alone is insufficient to induce marked apoptosis,
but inhibition of both pathways together has synergistic ef-
fects. Further, these results suggest that the effects of EGFR
inhibition are mediated, at least in part, by downstream inhibi-
tion of MAPK. However, other pathways are likely to be also
involved, as inhibition of EGFR is more effective than inhibition
of MEK (comparison of IC50 in Figure 1C versus Figure 5A).
Inhibition of BAD phosphorylation integrates the effects
of EGFR/MEK/MAPK and PI3K/Akt signaling on apoptosis
The BAD protein plays an important role in mediating the apo-
ptotic signal in cells deprived of growth factors. BAD is a BH3
domain protein that induces apoptosis by dimerizing with and
inactivating the antiapoptotic proteins Bcl-2 and Bcl-XL (Yang
et al., 1995). Growth factors prevent apoptosis, in part, by acti-
vating signaling pathways that result in the serine phosphoryla-
tion of BAD (Bonni et al., 1999; Zha et al., 1996). Phosphory-
lated BAD is bound to 14-3-3 protein and is thus unavailable
to interact with members of the Bcl-2 family (Zha et al., 1996).
In many cells, BAD is predominantly phosphorylated on serine
112, a site that is MAPK dependent (Bonni et al., 1999; Fang et
al., 1999; Scheid et al., 1999). BAD is phosphorylated on other
sites as well, including serine 136, an Akt-dependent site
(Datta et al., 1997). It was difficult to determine the phosphory-
lation state of endogenous BAD in MDA-468 cells with avail-
able reagents. In MDA-468 cells in which it was transiently
overexpressed, BAD was phosphorylated on serine 112 and
serine 136 (Figure 6A) and was found to be associated with
the 14-3-3 protein (Figure 6D). Serine 112 phosphorylation was
sensitive to EGFR and MEK inhibitors (Figures 6B and 6C), but
not to PI3K inhibitors or to PTEN induction (Figures 6A–6C).
In contrast, serine 136 was dephosphorylated in response to
manipulations that result in Akt inhibition (Figures 6A–6C), but
not to those that cause a decline in MAPK activation (Figures
6B and 6C). Similar results were also obtained in SKMG-3 cells
(Figure S2). Neither inhibition of serine 112 nor inhibition of ser-
ine 136 was sufficient to cause a significant decrease in BAD-
14-3-3 association (Figure 6D). However, the binding of BAD
to 14-3-3 was efficiently abrogated by the combination (Fig-
ure 6D).
To establish that activation of BAD requires inhibition of both
pathways and confirm that dephosphorylation of BAD is re-
sponsible for the synergistic induction of apoptosis, we trans-
fected wild-type BAD, the BAD mutants S112A and S136A, or
the double mutant S112A/S136A into MDA-468TR-PTEN cells
(Figure 6E). Maximal induction of apoptosis in wild-type
transfectants required inhibition of both pathways. BADS112A
transfectants had higher baseline apoptosis than wild-type,
and apoptosis was enhanced by induction of PTEN but not by
gefitinib. The BADS136A mutant had the opposite phenotype:
insensitivity to PTEN induction and enhancement by gefitinib.
The double mutant induced maximal apoptosis, which was in-
sensitive to inhibition of both pathways.
To determine whether BAD is directly involved in the apo-
ptotic response to gefitinib and PTEN expression, we usedCANCER CELL : OCTOBER 2005
A R T I C L EFigure 4. Activation of PI3K and Akt is independent of EGFR in PTEN-deficient tumor cells
A and B: MDA-468TR-PTEN and control cells were treated with or without Dox (100 ng/ml) (A). MDA-468TR-PTEN and control cells were pretreated with Dox
(100 ng/ml) overnight to induce PTEN and then treated with 3 M gefitinib (B). Cell lysates were immunoblotted with the indicated antibodies. IP was
done with EGFR antibody or control IgG followed by immunoblotting of tyrosine-phosphorylated EGFR and total EGFR (B).
C: MDA-468 and A431 cells were treated with 3 M gefitinib or DMSO (<0.1%) for 4 hr. IP was done with the indicated antibodies or control IgG followed
by immunoblotting with the indicated antibodies.
D: MDA-468 and A431 cells were treated with 3 M gefitinib or DMSO (<0.1%). Cell lysates were immunoprecipitated with HER3 or control IgG antibody,
and PI3K assays were performed as described.siRNA to knock down expression of endogenous BAD protein
in MDA-468TR-PTEN cells. In two different clones with stable
expression of BAD siRNA and 70%–80% decreased BAD ex-
pression, induction of apoptosis by gefitinib and PTEN expres-
sion was significantly reduced (Figures 6F and 6G). These data
support the idea that synergistic apoptosis induced by com-
bined inhibition of EGFR/MAPK and PI3K/Akt signaling is due
to activation of the BAD protein.
Induction of PTEN expression synergizes with EGFR
inhibitors to suppress MDA-468 xenograft growth in vivo
The synergistic proapoptotic effect of EGFR inhibition and
PTEN induction suggests that targeting both PI3K and EGFR
signaling may be a rational strategy for the treatment of tumors
with defective PTEN and active EGFR. We sought to determine
whether inhibition of both pathways in vivo would effectively
suppress tumor growth. Nude mice were injected subcutane-
ously with MDA-468TR-PTEN and vector control cells. Mice
with established tumors were treated with doxycycline in the
drinking water. Doxycycline effectively induced PTEN and
caused profound reduction in Akt phosphorylation but had no
effect on EGFR or MAPK phosphorylation (Figures 7B and 7C).
In contrast, gefitinib had no effect on Akt phosphorylation but
markedly inhibited phosphorylation of EGFR and MAPK, whichCANCER CELL : OCTOBER 2005fell within 5 hr of drug administration and remained depressed
for at least 24 hr (Figure 7C).
Induction of PTEN slowed tumor growth (p < 0.01), but the
growth suppression was reversible upon withdrawal of doxycy-
cline and loss of PTEN expression (Figure 7A). Doxycycline
treatment had no significant effects on tumor growth in vector
control mice (p > 0.05). In mice, the maximally tolerated dose
of gefitinib given daily for 5 days ranged from 150 to 200 mg/
kg. Treatment with gefitinib also slowed tumor growth, but nei-
ther PTEN induction nor gefitinib caused tumor regression or
completely prevented tumor growth (Figure 7D). However, gefi-
tinib in combination with PTEN induction synergistically sup-
pressed the growth of the tumor xenografts and caused tumor
regression (p < 0.01). Furthermore, caspase-3 was activated
synergistically by PTEN induction in combination with gefitinib
(Figure 7C). These results recapitulate the tissue culture data
and show that PTEN reexpression sensitizes tumor cells to in-
duction of apoptosis by EGFR inhibition in vivo as well as in
tissue culture.
Discussion
The EGFR receptor plays an important role in regulating the
proliferation and survival of normal epithelial cells. In various291
A R T I C L EFigure 5. The MEK/MAPK pathway in part mediates sensitization to EGFR in-
hibition
A and B:MDA-468TR-PTEN and control cells were treated with CI-1040 (MEK
inhibitor) or DMSO (<0.1%) with or without Dox (100 ng/ml) for 5 days (A).
MDA-468 cells were treated with CI-1040 and LY294002 for 5 days (B). Re-
sults are shown as a percentage of cell number relative to CI-1040-
untreated control cells.
C–F: MDA-468TR-PTEN and control cells were treated with CI-1040 or DMSO
(<0.1%) with or without Dox (100 ng/ml) for 72 hr (C). MDA-468 (D),
SKMG-3 (E), and SKMel-11 (F) cells were treated with CI-1040 and LY294002
for 72 hr (D and E) or the indicated times (F). Apoptotic cells (sub-G1) were
determined as in Figure 2A, and the results represent mean ± SE from two
or three independent experiments.model systems, overexpression, autocrine stimulation, and
mutation of EGFR have been shown to be transforming (De
Luca et al., 1999; Huang et al., 1997; Salomon et al., 1995).
Mutations in the EGFR gene have recently been identified in a
minority of non-small cell lung cancers, and their presence is
strongly correlated with clinical response to EGFR inhibitors
(Paez et al., 2004). A truncated, alternative form of EGFR is
often expressed in glioblastoma and is felt to play a role in their
pathogenesis (Ekstrand et al., 1994). However, it is difficult to
show that EGFR plays a role in the overwhelming majority of
tumors in which it is wild-type. Potent, selective inhibitors of
the EGFR tyrosine kinase have been developed, and they have
limited activity in tumor types that do not harbor EGFR muta-
tions (Paez et al., 2004).
EGF induces proliferation by activating a network of signal-
ing elements, including members of the STAT family, PLCγ,292Ras, and PI3K (Yarden and Sliwkowski, 2001). Genes encoding
components of these pathways are often mutated in malig-
nancy, especially K- and N-Ras, B-Raf, PI3K, and PTEN (Li et
al., 1997; Samuels et al., 2004; Tsao et al., 2004). Mutational
activation of pathways downstream of EGFR in cancer cells
may relieve their dependence on at least some aspects of
EGFR signaling. Indeed, it has been noted that, whereas nor-
mal colon and breast epithelial cell models are quite dependent
on EGFR for proliferation (Markowitz et al., 1990; Ram et al.,
2000), oncogenic transformation or malignant progression are
associated with increasing EGFR independence (Markowitz et
al., 1994). Furthermore, it has been recently shown that EGFR
and Ras mutations are mutually exclusive in lung cancer (Paez
et al., 2004; Pao et al., 2005).
The PTEN gene is frequently mutationally inactivated in hu-
man cancer, often in glioblastoma and prostate cancer (Li et
al., 1997), tumors in which truncated or wild-type EGFR is over-
expressed (Ekstrand et al., 1994; Thomas et al., 2001). We and
others have shown that these tumors are not dependent on
EGFR but are sensitized to EGFR inhibitors when PTEN is reex-
pressed (Bianco et al., 2003; She et al., 2003b). In this paper,
we confirm these data in a system in which PTEN expression
is under inducible control in tissue culture and in vivo. We have
gone on to demonstrate that reexpression of PTEN or pharma-
cological inhibition of PI3K causes PTEN-deficient tumor cells
to depend on EGFR for survival. Others have shown that PTEN
expression affects cell cycle progression as well (Ramaswamy
et al., 1999). The RB protein is mutated in MDA-468 (Sretha-
pakdi et al., 2000), which may explain the absence of an anti-
proliferative effect of PTEN. Inhibition of EGFR with gefitinib
synergizes with induction of PTEN or inhibition of PI3K to in-
duce caspase 3-dependent apoptosis in tissue culture and in
a xenograft model.
Apoptosis is marked and dependent upon inhibition of Akt
activity. Induction of PTEN expression downregulates Akt ki-
nase activity. Introduction of constitutively active, membrane
bound myr-Akt prevents PTEN-induced Akt inhibition and sen-
sitization of cells to gefitinib. Prior studies suggested the possi-
bility that reexpression of PTEN sensitizes cells to EGFR inhibi-
tors because it restores the EGFR dependence of PI3K/Akt
kinase signaling (Bianco et al., 2003; She et al., 2003b). Our
data here do not support this view. We show that induction of
PTEN causes a profound inhibition of the phosphorylation of
Akt and its substrates that is not further enhanced by EGFR
inhibitors. Furthermore, activated EGFR does not bind with
high affinity to the p85 regulatory subunit of PI3K and, in most
systems, PI3K activity is not dependent on EGFR signaling
(Olayioye et al., 2000; Soltoff et al., 1994). In MDA-468 cells,
we have demonstrated that both PI3K activity and p85 binding
to phosphotyrosine-containing proteins are not dependent on
EGFR. These data strongly suggest that the induction of apo-
ptosis by gefitinib is not due to further inhibition of PI3K or
Akt kinase. It is interesting to note that in MDA-468 we have
demonstrated (Figure 4) that p85 binding to HER3 is resistant
to doses of gefitinib that effectively inhibit both EGFR and
HER2. This suggests that HER3 is capable of being phosphor-
ylated by an unknown tyrosine kinase, which, in these cells, is
responsible for PI3K activation.
The ability of gefitinib to cooperate with inhibition of PI3K/
Akt signaling is due, in part, to its inhibition of MAP kinase
activity. EGFR activation leads to efficient activation of Ras sig-CANCER CELL : OCTOBER 2005
A R T I C L EFigure 6. Inhibition of MAPK-dependent serine
112 phosphorylation and Akt-dependent serine
136 phosphorylation of BAD causes synergistic
induction of apoptosis
A–C: MDA-468TR-PTEN, MDA-468TR-Vector, or
MDA-468 cells were transfected with wild-type
BAD. The transfected cells were treated with or
without Dox (100 ng/ml) (A); or pretreated with
Dox (100 ng/ml) overnight to induce PTEN and
then treated with 3 M gefitinib (B); or treated
with 3 M gefitinib, 1 M CI-1040, or 5 M
LY294002 for 4 hr (C). Cell lysates were immu-
noblotted for the indicated antibodies. Samples
were also immunoprecipitated with BAD anti-
body and immunoblotted for phosphorylated
BAD(Ser136).
D: MDA-468TR-PTEN cells transfected with BAD
were pretreated with Dox (100 ng/ml) overnight
to induce PTEN and then treated with 3 M gefi-
tinib for 4 hr. Cell lysates were immunoprecipi-
tated with BAD antibody or control IgG and im-
munoblotted for 14-3-3 protein.
E: MDA-468TR-PTEN cells were transfected with
empty vector or wild-type BAD, the BAD mu-
tants S112A and S136A, or the double mutant
S112A/S136A. The transfected cells were
treated with 3 M gefitinib or DMSO (<0.1%) with
or without Dox (100 ng/ml) for 72 hr. Apoptotic
cells (sub-G1) were determined as in Figure 2A,
and the results represent mean ± SE from three
independent experiments.
F and G: MDA-468TR-PTEN cells were either not
transfected (NT) or stably transfected with
negative control vectors or a mixture of four dif-
ferent siRNA vectors targeted against BAD. Im-
munoblotting was used to analyze the indi-
cated proteins in two different clones with
stable decreases in BAD expression (F). The transfected cells were treated with 3 M gefitinib or DMSO (<0.1%) with or without Dox (100 ng/ml) for 72 hr.
Apoptotic cells (sub-G1) were determined as in Figure 2A. The results are expressed as the increased levels of apoptosis by subtracting each of the
untreated controls and represent mean ± SE from three independent experiments (G).naling, and levels of MAP kinase activity are often elevated in
tumors in which EGFR is mutated or overexpressed (Chakra-
varti et al., 2002; Rojas et al., 1996). We show that reexpression
of PTEN or inhibition of PI3K also sensitizes cells to induction
of apoptosis by a potent and selective inhibitor of MEK kinase
activity. The data suggest that the survival of PTEN-deficient
tumors does not require signaling through Ras/MAP kinase but
that they rely on this pathway when PTEN expression is re-
stored and Akt is inhibited. In melanoma, activating mutations
of B-Raf constitutively activate MEK/MAPK signaling (Wan et
al., 2004) and commonly occur in association with inactivating
mutations of PTEN (Tsao et al., 2004). In Figure 5F, we show in
one such tumor cell, SKMel-11, that inhibition of PI3K alone
does not induce apoptosis but that it synergizes with MEK inhi-
bition.
Others have noted that the antitumor effects of inhibition of
two pathways, particularly MAP kinase- and PI3 kinase-depen-
dent pathways, are much greater than those elicited by inhibit-
ing either alone (Bedogni et al., 2004; Lee et al., 2003; Uzgare
and Isaacs, 2004). However, the molecular mechanism un-
derlying this phenomenon is poorly understood. BAD is a BH3
domain-containing protein that activates apoptosis, in part by
binding to and inactivating the antiapoptotic proteins Bcl-2 and
Bcl-XL (Yang et al., 1995). BAD is negatively regulated by path-
ways under the control of extracellular growth factors, whichCANCER CELL : OCTOBER 2005thereby inhibit apoptosis. BAD may be phosphorylated at mul-
tiple sites, prominently serine 112, a MAP kinase-dependent
site (Bonni et al., 1999; Fang et al., 1999; Scheid et al., 1999),
and serine 136, a site phosphorylated by Akt kinase (Datta et
al., 1997). Phosphorylation of these sites causes BAD to bind
to 14-3-3, sequestering it in the cytoplasm and preventing its
proapoptotic effects (Datta et al., 2000; Zha et al., 1996).
In primary breast epithelial cells, EGFR has been shown to
phosphorylate BAD on serine 112 (Gilmore et al., 2002). Gefi-
tinib selectively inhibits serine 112 phosphorylation and in-
duces apoptosis in these cells. We show here that, in MDA-
468, transfected BAD is highly phosphorylated on both serine
112 and serine 136 and forms a complex with 14-3-3. In agree-
ment with other reports (Fernando and Wimalasena, 2004; Gil-
more et al., 2002; Hayakawa et al., 2000), inhibition of EGFR or
MEK abrogates serine 112, but not serine 136 phosphorylation,
whereas, in contrast, induction of PTEN expression or inhibi-
tion of PI3K activity inhibits serine 136 but not serine 112. In-
hibiting either pathway alone slightly affects BAD association
with 14-3-3 and has little effect on apoptosis. Inhibiting both
pathways abolishes BAD binding to 14-3-3 and is associated
with dramatic apoptosis. Reduction of the expression of en-
dogenous BAD with siRNA markedly attenuates induction of
apoptosis in response to inhibition of both pathways.
The results suggest a model (Figure 8) in which, in normal293
A R T I C L EFigure 7. Induction of PTEN in combination with the EGFR inhibitor gefitinib synergistically suppresses PTEN-deficient and EGFR-overexpressing tumor growth
in vivo
A: Mice with established MDA-468TR-PTEN and vector control xenografts were treated with Dox (0.5 mg/ml) in the drinking water. The arrow indicates
withdrawal of Dox beginning on day 35. The results represent the mean tumor volume ± SE (n = 5 mice/group) from two independent experiments. *p <
0.01, MDA-468TR-PTEN + Dox versus MDA-468TR-Vector-Dox, MDA-468TR-Vector + Dox, or MDA-468TR-PTEN-Dox.
B: Mice with established MDA-468TR-PTEN xenografts were maintained with or without Dox (0.5 mg/ml) in the drinking water for 24 hr. Tumors were excised,
and H&E, Ki67, phosphorylated Akt, and activated caspase-3 were assessed by immunohistochemical staining.
C: Mice with established MDA-468TR-PTEN xenografts were maintained with or without Dox (0.5 mg/ml) in the drinking water and treated with gefitinib 150
mg/kg/day × 3 days or vehicle only (<0.3% lactic acid) as control. Tumors were excised pretreatment and at various times after the last dose of gefitinib
administration. The levels of phosphorylated EGFR(Tyr1068), Akt and MAPK, and total EGFR, PTEN, and activated caspase-3 were assessed by immu-
noblotting.
D: Mice with established MDA-468TR-PTEN xenografts were maintained with or without Dox (0.5 mg/ml) in the drinking water and treated with gefitinib 150
mg/kg/day p.o. × 5 days/week × 3 weeks or vehicle only (<0.3% lactic acid) as control. Dox was given to mice until the gefitinib treatment was finished.
Black rectangles represent gefitinib treatment weeks. The results represent the mean tumor volume ± SE (n = 5 mice/group) from two independent
experiments. *p < 0.01, MDA-468TR-PTEN + Dox/gefitinib versus MDA-468TR-PTEN-Dox, MDA-468TR-PTEN-Dox/gefitinib, or MDA-468TR-PTEN + Dox.cells, BAD phosphorylation at several sites integrates the anti-
apoptotic effects of multiple growth factor-mediated signaling
pathways. EGFR-dependent MAPK signaling plays a promi-
nent role in this regulation, and in experimental systems, inhibi-
tion of serine 112 phosphorylation by gefitinib induces apopto-
sis in normal mammary epithelia. However, in tumors in which
transformation is mediated by constitutive activation of Akt,
such as those in which PTEN is mutationally inactivated, serine
136 phosphorylation is sufficient to sequester BAD and inhibit
apoptosis. Normal MAPK-dependent serine 112 phosphoryla-
tion is rendered superfluous. Indeed, we have shown that in-
hibiting MAPK has little or no effect in tumor cells in which
the pathway is not activated by mutation (data not shown). In
systems terminology, the BAD protein acts as an “Or” logic
gate or switch; phosphorylation at either site in response to
either pathway is sufficient for its inactivation.
It follows that inhibition of the activated Akt signaling path-
way is not sufficient to activate apoptosis. When Akt is inhib-
ited in response to PTEN induction, the cell relies on EGFR/294MAPK signaling, the default physiologic pathway, to inactivate
BAD and prevent apoptosis. Under these conditions, inhibition
with gefitinib or an inhibitor of MEK signaling causes cell death.
It seems unlikely that BAD is the sole target that integrates the
effects of these pathways on survival. These data are important
as a heuristic model to explain interactions between normal
and oncogenically activated pathways (Figure 8). However, data
obtained with S112A and S136A mutants and BAD siRNAs sug-
gest that, in the MDA-468 system, BAD is the dominant target
responsible for the effects of both pathways on apoptosis.
Whether or not BAD plays this dominant role in other sys-
tems is unknown. We have demonstrated synergistic effects of
pharmacologic inhibition of PI3K in combination with inhibition
of EGFR or MEK in multiple other cellular systems (Figures 5E
and 5F, Figure S1, and data not shown). Inhibition of these
pathways has the predicted effect on phosphorylation of BAD
on serine 112 and serine 136 (Figure S2). However, the role
played by BAD in mediating the phenotypic consequences of
combined pathway inhibition in other models will require moreCANCER CELL : OCTOBER 2005
A R T I C L EFigure 8. A model for role of BAD as an apoptotic switch in PTEN-deficient
tumor cells
A: In PTEN-deficient tumor cells, activation of PI3K and Akt is EGFR indepen-
dent. The BAD protein acts as a switch that integrates the antiapoptotic
effects of the EGFR/MEK/MAPK and PI3K/Akt pathways.
B: Dephosphorylation of BAD abolishes BAD binding to 14-3-3 and is re-
quired for the synergistic induction of apoptosis in response to inhibition of
both pathways.detailed mechanistic studies in tissue culture and in vivo
models.
These data do have several important clinical implications.
They suggest that monotherapy with EGFR inhibitors would
not be effective in tumors with PTEN inactivation, even if they
express an activated form of EGFR. PTEN inactivation together
with EGFR overexpression occurs commonly in glioblastoma,
prostate cancer, and perhaps other tumors. Furthermore, in tu-
mors in which both pathways are mutationally activated, such
as some melanomas, inhibition of neither alone would be ex-
pected to affect tumor survival. The data provide a rationale
for therapy with combinations of signaling inhibitors. Although
transformation may be exquisitely dependent on a pathway ac-
tivated by a mutated oncogene, tumor cells may survive inhibi-
tion of this pathway by relying on the normal physiologic path-
way. The data suggest that, in tumors with PTEN loss that are
derived from EGFR-dependent lineages, it may be necessary
to block both EGFR/MAPK and PI3K/Akt kinase signaling. No
drugs that efficiently inhibit the PI3K/Akt kinase signaling in vivo
are currently available for clinical use, although many are in
early stages of development. Currently, the only potential ways
to inhibit this pathway clinically are with inhibitors of tyrosine
kinases that are known to drive PI3K in particular tumors
(HER2, IGF1R) (Garcia-Echeverria et al., 2004; Moasser et al.,
2001) or with inhibitors of Hsp90 that cause Akt degradation
(Basso et al., 2002).
Recent clinical results with EGFR inhibitors have questioned
whether wild-type EGFR is a significant therapeutic target
(Paez et al., 2004). The data presented here suggest three sce-
narios in which inhibition of wild-type EGFR could be useful:
first, as described here, in combination with drugs that inhibit
the oncogenic target in situations in which the EGFR drives
physiologic signaling; second, in tumors in which Akt activity
is low and EGFR-driven MAPK is responsible for cell survival;CANCER CELL : OCTOBER 2005third, in the occasional tumor in which Akt kinase is dependent
upon wild-type EGFR. Rational therapy will depend on de-
veloping the means to classify tumors in these terms.
Experimental procedures
Cell culture and reagents
The human cancer cell lines MDA-468 and A431 (ATCC, Manassas, VA)
were grown as described (Moasser et al., 2001). The glioblastoma cell line
SKMG-3 was provided by Christopher Thomas (Thomas et al., 2001) and
maintained in DMEM with 10% FBS. The melanoma cell line SKMel-11 was
obtained from Alan Houghton (MSKCC, New York, NY) and maintained in
RPMI 1640 medium with 10% FBS. Gefitinib was obtained from AstraZen-
eca Pharmaceuticals (Cheshire, United Kingdom); CI-1040 was obtained
from Pfizer (New York, NY); LY294002 and the caspase inhibitor Z-VAD-
FMK were from Calbiochem (La Jolla, CA); and doxycycline was from Sigma
(St. Louis, MO).
Cell proliferation and apoptosis assays
Cells were seeded in six-well plates at a density of 50,000 cells per well in
duplicate. The following day, cells were placed in fresh medium containing
indicated concentrations of drugs and allowed to grow for 4–6 days, and
subsequently harvested by trypsinization and counted using a Zeiss Coulter
Counter (Beckman Coulter, Miami, FL). To measure apoptosis, cells were
seeded in 100 mm dishes at a density of 8 × 105 cells per dish, and the
following day, cells were treated with drug or vehicle (DMSO) for the indi-
cated times. Both adherent and floating cells were harvested and stained
with ethidium bromide (Nusse et al., 1990). Detection and quantitation of
apoptotic cells (sub-G1 fraction) were performed by flow cytometric analy-
sis. To assay DNA fragmentation, both adherent and floating cells were
harvested. The fragmented DNA was extracted and determined as de-
scribed (She et al., 2003a).
Immunoblotting and immunoprecipitation
Cells were washed with PBS once, disrupted on ice for 30 min in NP-40
lysis buffer as described (Basso et al., 2002), and cleared by centrifugation.
Protein concentration was determined with BCA reagent (Pierce Chemical
Co., Rockford, IL). Equal amounts of protein (50 g) in cell lysates were
separated by SDS-PAGE, transferred to membranes, immunoblotted with
specific primary and secondary antibodies, and detected by chemilumines-
cence with the ECL detection reagents (Amersham Biosciences, Piscata-
way, NJ). Antibodies for p-EGFR(Tyr1068), p-Akt(Ser473), p-MAPK, p-BAD
(Ser112) and BAD(Ser136), activated (cleaved) caspase-3, cleaved PARP, total
Akt, and MAPK were from Cell Signaling Technology (Beverly, MA). Phos-
photyrosine (PY99), PTEN, and 14-3-3β (FL-246) antibodies were from
Santa Cruz Biotechnology (Santa Cruz, CA). The monoclonal BAD and
EGFR antibodies were from BD Biosciences (San Diego, CA). Other anti-
bodies include anti-PI3K p85 (Upstate Biotechnology, Waltham, MA), HER3
(Neomarkers; Ab-2, Fremont, CA), and β-actin (Sigma). For immunoprecipi-
tation, 500–1000 g of cell lysate protein were incubated overnight at 4°C
with the designated antibody, and then protein G-Sepharose (Amersham
Biosciences) was added for 3 hr while being rocked. Precipitates were
washed three times with lysis buffer and once with PBS, resuspended in
2× Laemmli buffer, and resolved by SDS-PAGE followed by immunoblot-
ting analysis.
Stable and transient transfections
MDA-468 cells were stably transfected with a tet-inducible PTEN vector
and named MDA-468TR-PTEN as described (She et al., 2003b). In this vec-
tor system, doxycycline binds to and interferes with the tet repressor, lead-
ing to unhindered activity of the CMV promoter and expression of the PTEN
cDNA insert. MDA-468 cells were also stably transfected with a tet-induc-
ible parent vector and used as vector-only controls. Transient transfections
were performed with Lipofectamine Plus reagent (Invitrogen, Carlsbad, CA)
according to the manufacturer’s instructions. The active myristoylated Akt
construct, pUSEamp/myr-Akt, was from Upstate Biotechnology. Wild-type
BAD and its mutants (BADS112A, BADS136A, and BADS112A/S136A) were
provided by Michael Greenberg (Datta et al., 1997). MDA-468, MDA-468TR-
Vector, and MDA-468TR-PTEN cells were seeded in 100 mm dishes at a
density of 3 × 106 cells/dish and transfected with 10 g of pUSEamp/myr-295
A R T I C L EAkt, wild-type BAD, or its mutants and Lipofectamine Plus reagent. After
24 hr, cells were placed in medium containing indicated concentration of
drugs for the indicated times, and then cells were harvested and analyzed
by immunoblotting or apoptosis assays as described above.
Knockdown of BAD protein by stable expression of siRNAs
MDA-468TR-PTEN cells were transfected with a pGB BAD siRNA vector
mixture of four different siRNA vectors targeted against BAD or pGB nega-
tive control vector (BioVison, Mountain View, CA) by using Lipofectamine
Plus reagent (Invitrogen). The stable transfectants were obtained by selec-
tion for G418 resistance (400 g/ml) and further analyzed by immunoblot-
ting BAD protein.
PI3K activity assay
PI3K activity was determined as described previously (She et al., 2003a). In
brief, cells were treated with 3 M gefitinib, harvested, and lysed. HER3-
associated PI3K was coimmunoprecipitated with monoclonal HER3 anti-
body (Neomarkers; Ab-4). PI3K activity was assayed in 250 M ATP
containing 10 Ci [γ-32P]ATP with phosphatidylinositol as substrate. The
product, PI3 phosphate, was resolved by thin layer chromatography and
detected by autoradiography.
Animal studies
Six-week-old athymic BALB/c female mice (NCI-Frederick Cancer Center)
were maintained in pressurized ventilated cages. MDA-468TR-Vector or
MDA-468TR-PTEN cells (1 × 107) were mixed 1:1 with Matrigel (Collabora-
tive Research, Bedford, MA) and injected subcutaneously into the right flank
(200 l/mouse). After 7–10 days, mice bearing tumors 6–7 mm in diameter
were randomized among control and treated groups. For induction of the
tetracycline-responsive promoter, mice received doxycycline (0.5 mg/ml) in
the drinking water. Gefitinib was administrated orally as a lactate salt (pH
5.2) at a dose of 150 mg/kg/day × 5 consecutive days each week for 3
weeks. Mice were weighed and tumors were measured with vernier cali-
pers. Tumor volumes were calculated with the following formula: π/6 ×
larger diameter × (smaller diameter)2. Unpaired Student’s t test was used
to assess statistical significance.
To analyze cellular markers, mice with established tumors were given
doxycycline (0.5 mg/ml) in the drinking water or treated with gefitinib at a
dose of 150 mg/kg/day for 3 consecutive days. Mice were sacrificed pre-
treatment and at the indicated times posttreatment. For immunoblotting,
tumor tissue was homogenized in RIPA buffer as described (She et al.,
2003b). For immunohistochemical staining, tumors to be examined were
excised promptly after euthanasia and immediately placed in 4% paraform-
aldehyde. The tumors were fixed overnight in paraformaldehyde and then
dehydrated and embedded in paraffin. Sections of 8 m were cut for hema-
toxylin and eosin staining and Ki-67, p-Akt(Ser473), and activated caspase-3
immunochemical staining.
Supplemental data
The Supplemental Data include two supplemental figures and can be found
with this article online at http://www.cancercell.org/cgi/content/full/8/4/287/
DC1/.
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